Introduction
Helicobacter pylori infections induce vigorous systemic and mucosal humoral responses that are predominantly mediated by IgA, IgG, and IgM. These immunoglobulins are detectable in sera, gastric aspirates, or stomach extracts (1, 2) . Humoral immunity against H. pylori can effectively prevent infection and reduce colonization but does not lead to eradication of H. pylori-induced gastritis (2) .
Absorption of dietary cobalamin (vitamin B 12 ; vB 12 ) depends on several factors, including acid-dependent deproteinization of vB 12 . Only free vB12 can form a complex with the intrinsic factor (IF). The vB12-IF complex is then absorbed by mucosal cells via its specific receptor (cubilin) in a calcium-dependent fashion. Gastric parietal cells are responsible for production of both hydrochloric acid and IF. Absorbed vB12 is then stored in the liver.
Some H. pylori patients develop autoantibodies directed against gastric parietal H + /K + -ATPase cells (APCAs), resulting in achlorhydria and increased infection with H. pylori, which in turn contributes to gastric damage and atrophy of the corpus (2) .
Autoimmunity may destroy parietal cells that are responsible for hydrochloric acid and IF production, resulting in achlorhydria and failure to deproteinize vB 12 and/or failure to produce IF. Consequently, the vB 12 -IF complex fails to form, leading to malabsorption of vB 12 and, potentially, to pernicious anemia. Hence, patients diagnosed with vB 12 deficiency as a result of APCAs or anti-IF antibodies were excluded, since their vB 12 deficiency cannot be directly and solely attributed to H. pylori infection (3-6; see Section 2.2).
In this work, we investigated the correlation between serum anti-H. pylori IgA antibodies and vB 12 . The role of contaminating variables on this correlation was explored as well.
Helicobacter pylori dyspeptic symptoms such as epigastric pain, nausea, heartburn, and vomiting (7, 8) .
Informed consent was obtained from each participant (patients and healthy volunteers). Interviews and questionnaires were administered in Arabic to all participants. Sera were collected starting November 2009 through February 2010.
Collected data regarding smoking habits, age, sex, symptoms, and causes of vB 12 deficiency were recorded for each participant. A healthy volunteer was defined as one who did not suffer from disorders or stomach problems, i.e. absence of gastritis.
Subject exclusion criteria
In order to focus our research on the relationship between Helicobacter pylori infection and vB 12 deficiency, factors and cases known to affect the state of vB 12 levels were excluded, with the exception of H. pylori infection. Subjects suffering from known causes of vB 12 deficiency other than H. pylori infection were excluded and patients suffering from other chronic diseases that may interfere with the interpretation of the results of this study were excluded as well.
The exclusion criteria were as follows: age <18 or >50 years; diabetic patients; celiac disease; patients with a history of (steroid or nonsteroid) antiinflammatory drug, antiacid, H 2 -receptor antagonist, or proton pump inhibitor intake in the previous month; history of treatment of H. pylori infection; history of drug vB 12 intake; patients with gastrointestinal bleeding, renal failure, liver diseases, thyroid disorders, autoimmune diseases, previous GI surgery, folate deficiency, strict vegetarian, neoplasia, alcohol intake, rheumatoid arthritis, or pregnancy.
Exclusion of vB 12 -deficient patients showing anti-IF activity
The presence of anti-IF antibodies in sera of vB 12 deficient patients was determined using an IF ELISA kit (Alpha S.A/ NV, Belgium), following the manufacturer's instructions. Samples were diluted to 1:51, mixed, and 100 μL of each sample dispensed into a designated microwell. After 30 min of incubation at room temperature, microwells were washed with diluted washing buffer (1:20) and treated with 100 μL of conjugate for 30 min. Afterwards, substrate (100 μL) was added and incubated for 10 min at room temperature. After adding the stop solution, absorbance was recorded at 450 nm. A sample was considered negative when the binding index (BI) was less than 1.0; a sample was considered positive when BI was >1.0. All positive subjects were excluded from the study.
Exclusion of subjects showing APCAs
APCAs were determined in sera with a commercial enzyme immunoassay (Varelisa Parietal Cell Antibodies, Pharmacia Diagnostics, Germany). All sera samples with vB 12 deficiency (diluted 1:101) were processed according to manufacturer's instructions and absorbance was read at 450 nm within 30 min of adding stop solution in reference to absorbance recorded at 620 nm. A sample was scored as negative when the ratio was <1.0, a sample was scored as equivocal when the ratio ranged between 1.0 and 1.4, and a sample was positive when the ratio was >1.4. All positive subjects were excluded from the study.
The decision to exclude these subjects (Sections 2. 12 was quantified in sera using AxSYM Abbott automation system (Abbott Laboratories, USA), a method based on microparticle-enzyme-IF assay; the results were expressed in pg/mL. The cutoff level for vB 12 deficiency is <200 pg/mL, according to the manufacturer's instructions.
The following scale was adopted to estimate and define vB 12 level of deficiency among patients: severe deficiency when the mean vB 12 value is <75 pg/mL of serum, moderate deficiency when the mean vB 12 value is between 75 and 150 pg/mL, and mild deficiency when the mean vB 12 ranges from 150 to <200 pg/mL (200 pg/mL being the cutoff value between deficiency and sufficiency). Normal vB 12 range is >200 to 900 pg/mL (11).
Quantification of serum anti-Helicobacter pylori IgA
Anti-Helicobacter pylori IgA concentration was determined in sera samples using an H. pylori IgA ELISA kit (NovaTec Immundiagnostica; GmbH, Germany) as instructed by the manufacturer. Microwell plates and reagents were brought to room temperature (25 °C). Washing buffer (diluted 1:19 in distilled water) and serum samples (10 μL) were mixed with 0.99 mL IgA diluents. Then 100 μL of each standard (A, B, C, D) and diluted samples were placed into their designated wells, covered, and incubated at 37 °C for 60 min. Microwells were washed 3 times with 300 μL diluted washing buffer. Except for blank wells, 100 μL of Helicobacter pylori anti-IgA conjugate were added to each well. Plates were incubated in the dark for 30 min at room temperature. This was followed by another cycle of washing as above. Substrate (100 μL) was added to each well (including the blanks), covered, and incubated for 15 min at room temperature (25 °C) in the dark. Stop solution (100 μL) was added to each well (including the blanks), covered, and incubated for 15 min at room temperature in the dark. The blue/orange color of wells was scored for each well using photometric measurements at 450/620 nm within 30 min. The scale recommended by manufacturer was adopted. H. pylori infection was considered reactive if the mean serum IgA value was >20 NTU/mL, equivocal if the mean serum IgA titer fell between 15 and 20 NTU/ mL, and nonreactive if the mean serum IgA value was <15 NTU/mL (healthy or immune-tolerant).
Statistical analysis and graphs
Collected data were analyzed using Microsoft Excel (2007) and the online Social Science Statistics (http://www. socscistatistics.com/tests/mannwhitney/Default.aspx) (10) . Analyses and calculations included means, standard deviation, median, upper and lower limits, Mann-Whitney significant differences between control and patient groups at P < 0.05 and P < 0.01, and open form P-values.
Correlation analyses were based on Excel Pearson's R 2 and its square root (r), while confidence was determined using the two-tailed "r" distribution at P < 0.05 and P < 0.01 and open form P-values. Additionally, Pearson's correlation levels were analyzed after removing potential contaminating variables (factors) which included subjects with abnormal vB 12 or abnormal IgA titers and some outlier values as described in Section 3. 12 and IgA Levels of vB 12 and anti-Helicobacter pylori IgA in sera are presented in Figure 1 and the Table. Means and medians for each of the four groups of subjects were obtained. The median of serum vB 12 level for patients (150; range 59-198 pg/mL serum) was significantly different from the median for the control group (330; range 187-731 pg/mL serum, P = 0.00001) and the medians were significantly different at P < 0.05 and P < 0.01 (Mann-Whitney U-test) ( Figure  1 and Table) .
Results

Levels of vB
Significant differences (P < 0.05 and P < 0.01; P = 0.00001) were recorded for IgA levels, indicating that the median IgA for patients (40; range 6-153 NTU/mL serum) was different from the median for control subjects (range 0-140 NTU/mL serum) (6) . Severe vB 12 deficiency was observed in 4.5% (6/133 patients); moderate vB 12 deficiency in 48.9% (65/133). The remaining 62 patients (46.6%), showed mild vB 12 deficiency. Healthy control subjects had normal vB 12 levels, ranging from 212 to 756 pg/mL serum with the exception of one subject, a 35-yearold female that showed vB 12 deficiency (187 pg/mL) and high IgA titer (22 NTU/mL).
The majority of healthy participants (85.7%, 90/105) had background levels of anti-Helicobacter pylori IgA (0 to 14 NTU/mL). Fifteen control subjects (14.3%; 15/105 including the 35-year-old female with vB 12 deficiency) had IgA titers higher than 15 NTU/mL, ranging from 22 to 140 NTU/mL serum. The vast majority of vB 12 -deficient patients (84.2%; 112/133) had IgA titers higher than 20 NTU/mL, while the remaining patients (15.8%; 21/133) had low levels of IgA (Table) . The two groups (15 control and 22 patient subjects) were viewed as contaminating factors (Table and Section Table. titers >15 NTU/mL) were excluded, a stronger correlation coefficient was obtained (r = -0.539; P = 0.00001). Upon the omission of 13 patient subjects showing IgA titers <15 NTU/mL, the obtained correlation coefficient was r = -0.521; P = 0.00001. When both contaminating groups (15 controls and 13 patients) were omitted, the correlation became stronger (r = -0.579; P = 0.00001). A further omission of a group of controls (7 subjects) showing high vB 12 concentration (>537 pg/mL serum) a further increase in correlation was obtained (r = -0.615; P = 0.00001). The results showed significant Pearson's correlation both at P < 0.05 and P < 0.01.
Discussion
vB 12 stores
The liver is the main vB 12 store; it stores 80% of total body vB 12 (2 to 5 mg). Stored vB 12 will last an adult individual for 3-5 years in the absence of significant vB 12 intake, or for 5-6 years when vB 12 intake is insufficient. In addition, vB 12 undergoes a daily enterohepatic circulation where 1 to 10 µg is excreted in bile and reabsorbed (6 (12) , the inhibition of vB 12 absorption by H. pylori infection cannot yet be verified.
Identification of contaminating variables that influenced correlation analysis
This study identified and excluded at least five contaminating factors; these factors would have blurred the correlation (10, 21) . This study determined the actual negative state of correlation between the two variables (r = -0.45; P = 0.00001). The correlation between H. pylori infections as indicated by serum levels of anti-H. pylori IgA and vB 12 deficiency was affected by contaminating variables; a fraction of the control group (15/105; 14.3%) showed high IgA titers, suggesting possible asymptomatic H. pylori infection. Another contaminating factor appeared among patient subjects in the form of IgA titers lower than the cutoff value (<15 NTU/mL serum). The impact of these factors on correlation was demonstrated when they were excluded from data before analysis. The omission of 15 contaminating control subjects caused an increase in correlation (r = -0.538). A similar contribution was made upon omission of 13 patients showing IgA titers lower than 15 NTU/mL (r = -0.521). When both contaminating variables were omitted, a stronger correlation emerged (r = -0.58). Omission of seven (6.6%) additional control subjects showing high levels of vB 12 (536-731 pg/mL serum; Figure 2A ) increased the correlation coefficient to r = -0.61. All correlations between vB 12 and IgA were significant; P = 0.00001. Figure 2 illustrates that subjects can be categorized into one of four clusters based on the combined level of vB 12 and anti-H. pylori IgA. Cluster A reflects normal healthy subjects with high vB 12 (>200 pg/mL) and low IgA (<15 NTU/mL). Cluster B contains healthy controls with high vB 12 but with elevated anti-H. pylori IgA (>15 NTU/ mL), which may be indicative of asymptomatic infection or recent exposure. Among patients with mild vB 12 deficiency (>150 but <200 pg/mL), cluster C showed poor IgA response, whereas cluster D subjects showed high or exaggerated IgA titers (subcluster D2 12 and low IgA (typical normal healthy control subjects), B: high vB 12 and high IgA (possible asymptomatic patients; a potential contaminating factor, see Section 4), C: low vB 12 and low IgA (patients not responding to infection; another potential contaminating factor), D: low vB 12 and moderate or high IgA (majority of typical patients); D1: normal patients (IgA < 124), D2: a subset of patients showing exaggerated IgA levels (>144 NTU/mL serum). a significant IgA immune response against H. pylori (i.e. they are immune-tolerant). Third, vB 12 deficiency among cluster C patients, or some of them, was the result of a factor independent of H. pylori. Exaggerated IgA levels observed in some patients (Figure 2, D2 ), may be due to repetitive exposure to living or dead H. pylori antigens (e.g., drinking H. pylori-contaminated or chlorinated well water). Another possibility resides in the potency of the subject's immune response to different H. pylori antigenic variants. 4.4. Incidence and baseline of asymptomatically infected population A conclusion regarding the incidence and baseline of an asymptomatically infected population was calculated to be approximately 14.3% (15/105) as represented by the high titer (>15 NTU/mL serum) of anti-H. pylori IgA among normal control subjects aged 18 to 50 years from the Hebron area. In an earlier study by Serin et al. (24) , 25% of healthy children were PCR-positive for H. pylori (24) . Since some of the children were only transiently infected while others may have progressed to become symptomatic (25) , it is likely that the percentage of asymptomatic subjects will decrease (i.e. <25%); accordingly it is likely that the baseline falls somewhere above 14.3% and below 25%.
Anomalies among subjects
In 9.8% of patients (13/133), IgA level did not predict the state of H. pylori infection ( Figure 2C) ; IgA titers were below the cutoff value of the test (15 NTU/mL serum). Possible antigenic variants of H. pylori or other microbes may have caused gastritis and cannot be detected by the IgA test used in this study. Another possibility is that some subjects (including control subjects) were immunetolerant to the H. pylori-targeted antigen. This category of IgA-negative subjects, in addition to false negative test results among all subjects, will shift the base line to a level higher than 14.3% when taken into consideration.
Additional studies across a given population are needed to obtain a realistic profile of the epidemiology of H. pylori infections.
Conclusions
Infection with H. pylori was negatively correlated to serum levels of vB 12 and may contribute to this deficiency. If other categories (e.g., individuals aged <18 and >50) and factors are to be included in similar future studies, the baseline of asymptomatically infected healthy subjects may be significantly higher than 14.3%. Serum level of anti-H. pylori IgA appears to be a good indicator of risk of developing vB 12 deficiency. It is our recommendation that subjects showing high IgA titers should be treated for H. pylori, monitored, and prophylactically treated for vB 12 deficiency. Failure of the IgA test to predict acute or chronic H. pylori infections in 9.8% of patients justifies the need for an additional supplementary or alternative test capable of detecting H. pylori in these and similar subjects, including apparently healthy subjects. the Alia Governmental Hospital, Hebron, Palestine, and all subjects who made this study possible through their complete support and collaboration. The authors would like to thank Dr Mazen Salman for his support and suggestions. This work was part of Mr Dudeen's graduate work towards his master's degree. Pearson's, r = -0.45 P = 0.00001
Correlat on between serum vB 12 and IgA vB 12 pg/mL serum IgA NTU/mL serum Figure 3 . Correlation between vB 12 levels and H. pylori infection (IgA). Scatter distribution of vB 12 vs. IgA for all 238 subjects. A negative Pearson's correlation was established (r = -0.45 for original data; P < 0.05 and P < 0.01; P = 0.00001).
